Market access risk in hematology

Hematology is the laboratory of rare-disease reimbursement. Its conditions are counted in hundreds or a few thousand patients per country — haemophilia, the complement-driven anaemias, immune thrombocytopenia, sickle cell disease — and its medicines include the first one-time gene therapies to reach a payer's desk, priced in the millions for a benefit meant to last a lifetime. Payers have built their orphan-drug machinery largely on this field: special assessment routes, outcomes-based contracts, annuity payments, and a close watch on whether a new drug adds an outcome or only a convenience to a disease already well treated. This page brings together MARA's independent assessments of reimbursement risk across the field.

What payers ask in hematology

Is the gain an outcome, or a convenience? Several blood disorders are already well controlled — bleeding prevented, haemoglobin held — by medicines payers have long reimbursed. A new drug that is taken less often or by mouth asks the payer to pay for convenience. Payers do pay for it, but at a price close to the old standard, not a new one.

How do you price a lifetime in one payment? One-time gene therapies replace decades of prophylaxis with a single infusion. Payers ask how long the effect lasts, how many patients will need their old treatment back, and how to pay for a benefit that is promised rather than yet observed — which is why these drugs arrive with outcomes-based agreements and instalment schemes.

What is the comparator in a crowded rare field? Rare does not mean alone. In complement disease or haemophilia a new drug may be the fourth or fifth option, and payers compare it with the one they already reimburse, at the price they already pay — the orphan premium goes to the first drug in a disease, rarely to the next.

Does the blood count stand for the patient? Haemoglobin, platelets, bleeding rates: the field's endpoints are numbers from the laboratory. Payers accept them where the link to how a patient lives is established, and ask for fatigue, transfusions avoided, hospital days and quality of life where it is not — in trials small enough that every patient counts.

The MARA record in hematology

Hematology holds more than twenty dated assessments in the MARA catalogue: haemophilia from long-acting factor to gene therapy, paroxysmal nocturnal haemoglobinuria across the complement classes, immune thrombocytopenia, sickle cell disease and beta-thalassaemia, the myeloproliferative neoplasms, chronic neutropenia, amyloidosis and the rarer blood cancers of the field. Each report answers the same payer questions, carries its "as of" date, and stays on the record — when the evidence moves, a newer vintage replaces the older one visibly, never silently. Assessments are produced on MARA's own initiative for awareness; the current MARA Rating for any drug is available on request.

Current assessments (23)

Selected commentary

The business case for hemophilia gene therapy still isn’t adding up

For how a MARA Rating is built, see the methodology and what a MARA Rating is. To request the current rating for any drug in this area, use the contact form.